N/A N=12 Lactic Acidosis During and After Seizures
Epilepsy
Primary: Salivary Lactic Acid Levels With Seizures — 8.16 mmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 The Various Effects of Gaseous Albuterol on Serum Lactate
Asthma
Primary: Number of Subjects With a Change From Baseline Serum Lactate Following a One Hour Albuterol Nebulizer Treatment. — -0.15; 0.77 mmol/L
Early Phase 1 N=30 Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?
Hyperlactatemia
Primary: Change in Mean Lactate Level of the LR Group Compared to the NS Group. — 0.93; 0.37 mmol/L
N/A N=458 Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
Sepsis · Disease Progression · Septic Shock
Primary: Proportion of the Patients Who Require Vasopressor/Mechanical Ventilator — 53; 21 participants
N/A N=34 Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Parkinson's Disease · Multiple Sclerosis
Primary: Blood Lactate Response — 1.7; 1.6; 1.2; 2.3 mmol/L
Phase 1 N=9 Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
Malignant Central Nervous System Neoplasm · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Number of Participants With Grade 2 or Higher Toxicities — 0; 0 Participants
Phase 2 N=250 Rapid Administration of Carnitine in sEpsis
Septic Shock
Primary: Delta SOFA Score — -1.8; -0.34; -1.68; -2.15 units on a scale
N/A N=66 Intravenous Fluids in Adults With Diabetic Ketoacidosis in the Emergency Department
Diabetic Ketoacidosis
Primary: Patient Recruitment Rate (Feasibility Outcome) — 66 Participants
N/A N=17 Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
N/A N=24 Effect of Lactose on Blood Lipids
Cardiovascular Risk Factor · Lipaemia · Metabolic Disease
Primary: Postprandial Changes in Plasma Triglyceride Concentrations — 51; 90; 98 mmol/L x 360 min
N/A N=480 Maternal Lifestyle and Neonatal Hypoglycemia
Hyperinsulinemia · Miscarriages · Pregnancy
Primary: Neonatal Hypoglycemia — 3; 15 neonates
Phase 2 N=4 L-Carnitine in Peritoneal Dialysis
End-Stage Renal Disease
Primary: Long Dwell Ultrafiltration — 2167 milliliters
N/A N=28 HYBRID: Hydrogen Breath Test in Lactose Digestion
Lactose Intolerance
Primary: Log of First Postprandial Peak Change of Hydrogen Concentration — 1.21; 1.10; 3.38; 3.59 log(ppm) — p=0.0801
Phase 3 N=59 Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables
Anesthesia
Primary: Change in Base Deficit — -1.5; -1.2; -0.5 mEq/L
N/A N=15 Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline
Dyspnea · Lactic Acidosis · Muscle
Primary: Blood Lactate Change — 1.19; 1.22; 1.11; 1.05 mmol/L
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=170 TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients
Hyperglycemia
Primary: Mortality — 36 mortality rate
Phase 2 N=2 Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
Phase 2 N=88 Thiamine as a Metabolic Resuscitator in Septic Shock
Septic Shock
Primary: Lactate Level 24 Hours After the First Study Medication Dose — 2.6; 2.5 mmol/L — p=0.40
Phase 3 N=40 Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis
Parenteral Nutrition Associated Cholestasis
Primary: Number of Participants With Parenteral Nutrition Associated Cholestasis — 6; 6 Participants — p=0.94